Thermo Fisher TMO is down 31% despite raised guidance
TMO boasts 82% recurring revenue - the ultimate healthcare stock analysis: buy or sell? 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down Thermo Fisher Scientific Inc. (TMO) and its resilient business model driven by 82% recurring revenues and strategic expansion into AI-driven laboratory workflows. With shares trading at an attractive 16.88 times NTM EV/EBITDA, the key question for investors is whether its temporary…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.